In subcutaneous tumors and lung metastases, a combined treatment of TUSC2 and anti-PD-1 promoted an increase in tumor-infiltrating NK and CD8 T cells, whereas the MDSC and Treg levels decreased. The gene discussed is PDCD1; the disease is neoplasm.